News Release

Orsini Specialty Pharmacy, Carlyle and Consonance Capital Partners Announce Strategic Partnership

Investment positions Orsini Specialty Pharmacy for continued expansion of patient access and support services across therapies for highly complex and rare diseases

ELK GROVE VILLAGE, Ill., Feb. 11, 2022 -- Orsini Specialty Pharmacy (“Orsini”), the leading independent specialty pharmacy focused on rare diseases, gene therapies and complex conditions, funds managed by global investment firm Carlyle (NASDAQ: CG), and Consonance Capital Partners, a healthcare-focused private equity firm, today announced a strategic partnership to position Orsini to further expand patient access to therapies that treat rare diseases and chronic conditions. Terms of the transaction were not disclosed.

Providing patients with comprehensive and compassionate care since 1987, Orsini's high-touch care model centers around experienced, therapy-specific care teams that provide personalized care to patients based on their specific conditions and treatments. The company's comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services.

“We are excited to welcome a new partner with a demonstrated track record of success in the healthcare industry and a shared passion for patient care,” said Mike Fieri, Founder and CEO of Orsini. “Carlyle brings to Orsini an extensive network across the life sciences and pharmaceutical services industries. Their unique resources and expertise will help us strengthen our high-touch service model for patients and enhance our service offerings for manufacturer customers.”

“We believe Orsini’s innovative patient-centric approach and consistent culture of care can improve quality and lead to a strong value proposition for patients, manufacturers, and payors,” said Joe Bress, Managing Director at Carlyle. “We are excited to partner with Orsini and Consonance to help further expand upon Orsini’s proven model of patient care targeting those who need it most.”

“At Consonance, we pride ourselves on investing in companies that improve lives and patient care, which is the reason we originally partnered with the Orsini team in 2019,” commented Javier Starkand, Partner at Consonance Capital Partners. “We have been thoroughly impressed with Orsini’s high quality approach to date, and we remain committed to helping nurture their existing culture and focus on high quality care that has been fundamental to their success and which is closely aligned with our investment principles.”

About Orsini

Providing patients with comprehensive and compassionate care since 1987, Orsini is the leading independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions. Orsini's high-touch care model centers around experienced, therapy-specific care teams that provide personalized care to patients based on their specific conditions and treatments. The company's comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services. Headquartered in Elk Grove Village, IL, Orsini Specialty Pharmacy holds accreditations with URAC, the Accreditation Commission for Health Care (ACHC), ACHC's Distinction in Rare Diseases and Orphan Drugs, The Joint Commission, and the National Association of Boards of Pharmacy (NABP). Further information is available at www.orsinispecialtypharmacy.com

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $301 billion of assets under management as of December 31, 2021, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs nearly 1,850 people in 26 offices across five continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.

About Consonance Capital Partners

Consonance Capital Partners invests in private companies in the lower middle market of the U.S. healthcare industry with an emphasis on businesses driving efficiency, cost containment, and high quality clinical care to patients. Consonance Capital Partners participates in growth equity, leveraged buyout, and recapitalization transactions. For more information, visit www.consonancecapitalpartners.com

Consonance Capital Partners Media Contact:

Whit Clay
Sloane & Company
T: 917-601-6012
wclay@sloanepr.com

Carlyle Media Contact:

Brittany Berliner 
Phone: +1 (212) 813-4839 
brittany.berliner@carlyle.com